GlaxoSmithKline plc (GSK, NYSE: GSK) delivered strong 2025 financial results, with total revenues rising 7% in constant currency to GBP 32.67 billion (USD 44.7 billion), driven by double-digit growth in Respiratory/Immunology, Oncology, and HIV. CEO Luke Miels highlighted broad-based performance, with specialty medicines up 17% and key franchises—including Shingrix, Nucala, Benlysta, and Jemperli—exceeding expectations. The UK-based pharma giant confirmed 2026 guidance of 3-5% turnover growth, supported by regulatory milestones for Exdensur, linerixibat, and bepirovirsen.
Forward‑Looking Statements This brief contains forward‑looking statements regarding GSK’s 2026 revenue growth, Exdensur commercial launch trajectory, and bepirovirsen regulatory approval timelines. Actual results may differ due to competitive dynamics in asthma (dupilumab, tezepelumab), RSV vaccine market saturation, and hepatitis B functional cure validation.-Fineline Info & Tech
Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.
